BEYOND AESTHETICS: BOTULINUM TOXIN TYPE A AS AN EMERGING ANTIDEPRESSANT STRATEGY
DOI:
https://doi.org/10.31435/ijitss.2(50).2026.5358Keywords:
Botulinum Toxin Type A; Major Depressive Disorder; Facial Feedback Hypothesis; Treatment-Resistant Depression; AntidepressantAbstract
Major depressive disorder remains one of the most burdensome psychiatric conditions worldwide, and a substantial proportion of patients continue to suffer despite available treatments. This narrative review examines an unexpected therapeutic candidate: botulinum toxin type A (BoNT/A), a bacterial neurotoxin long used in aesthetic medicine to reduce facial frown lines, which has emerged as a promising antidepressant intervention. The review synthesises clinical evidence from randomised controlled trials and meta-analyses, alongside mechanistic data from neuroimaging and preclinical studies, to evaluate the efficacy, safety, and biological plausibility of this approach. The findings consistently indicate that a single injection of BoNT/A into the glabellar region produces meaningful and durable improvements in depressive symptoms. The proposed mechanisms are scientifically compelling: by paralysing the muscles responsible for frowning, BoNT/A disrupts a feedback loop between facial expression and emotional processing in the brain, modulates activity in key mood-regulating structures, and triggers neurochemical changes associated with recovery from depression. The treatment is well tolerated, with only mild and transient side effects. Although larger confirmatory trials are needed, BoNT/A represents a genuinely novel, accessible, and mechanistically grounded addition to the therapeutic landscape of depression.
References
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., et al. (2018). Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. The Lancet, 391(10128), 1357–1366. https://doi.org/10.1016/S0140-6736(17)32802-7
Opbroek, A., Delgado, P. L., Laukes, C., McGahuey, C., Katsanis, J., Moreno, F. A., & Manber, R. (2002). Emotional blunting associated with SSRI-induced sexual dysfunction: Do SSRIs inhibit emotional responses? International Journal of Neuropsychopharmacology, 5(2), 147–151. https://doi.org/10.1017/S1461145702002870
Goldbloom, D. S., & Gratzer, D. (2020). Barriers to brain stimulation therapies for treatment-resistant depression: Beyond cost effectiveness. The Canadian Journal of Psychiatry, 65(3), 193–195. https://doi.org/10.1177/0706743719893584
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Cha, D. S., Ogendahl, A., Fagiolini, A., et al. (2021). Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: An international expert opinion on the available evidence and implementation. American Journal of Psychiatry, 178(5), 383–399. https://doi.org/10.1176/appi.ajp.2020.20081251
Finzi, E., & Wasserman, E. (2006). Treatment of depression with botulinum toxin A: A case series. Dermatologic Surgery, 32(5), 645–649. https://doi.org/10.1111/j.1524-4725.2006.32136.x
Darwin, C. (1872). The expression of the emotions in man and animals. John Murray.
James, W. (1884). What is an emotion? Mind, 9(34), 188–205. https://doi.org/10.1093/mind/os-IX.34.188
Alam, M., Barrett, K. C., Hodapp, R. M., & Arndt, K. A. (2008). Botulinum toxin and the facial feedback hypothesis: Can looking better make you feel happier? Journal of the American Academy of Dermatology, 58(6), 1061–1072. https://doi.org/10.1016/j.jaad.2007.10.649
Havas, D. A., Glenberg, A. M., Gutowski, K. A., Lucarelli, M. J., & Davidson, R. J. (2010). Cosmetic use of botulinum toxin-A affects processing of emotional language. Psychological Science, 21(7), 895–900. https://doi.org/10.1177/0956797610374742
Davis, J. I., Senghas, A., Brandt, F., & Ochsner, K. N. (2010). The effects of BOTOX injections on emotional experience. Emotion, 10(3), 433–440. https://doi.org/10.1037/a0018690
Soussignan, R. (2002). Duchenne smile, emotional experience, and autonomic reactivity: A test of the facial feedback hypothesis. Emotion, 2(1), 52–74. https://doi.org/10.1037/1528-3542.2.1.52
Niedenthal, P. M. (2007). Embodying emotion. Science, 316(5827), 1002–1005. https://doi.org/10.1126/science.1136930
Hennenlotter, A., Dresel, C., Castrop, F., Ceballos-Baumann, A. O., Wohlschlager, A. M., & Haslinger, B. (2009). The link between facial feedback and neural activity within central circuitries of emotion: New insights from botulinum toxin-induced denervation of frown muscles. Cerebral Cortex, 19(3), 537–542. https://doi.org/10.1093/cercor/bhn104
Kim, M. J., Neta, M., Davis, F. C., Ruberry, E. J., Dinescu, D., Heatherton, T. F., et al. (2014). Botulinum toxin-induced facial muscle paralysis affects amygdala responses to the perception of emotional expressions: Preliminary findings from an A-B-A design. Biology of Mood & Anxiety Disorders, 4(1), Article 11. https://doi.org/10.1186/2045-5380-4-11
Stark, S., Stark, C., Wong, B., & Brin, M. F. (2023). Modulation of amygdala activity for emotional faces due to botulinum toxin type A injections that prevent frowning. Scientific Reports, 13, Article 3333. https://doi.org/10.1038/s41598-023-29280-x
Finzi, E., Rosenthal, N. E., & Heiser, M. A. (2023). Botulinum toxin treatment for depression: A new paradigm for psychiatry. Toxins, 15(5), Article 336. https://doi.org/10.3390/toxins15050336
Wollmer, M. A., Magid, M., Kruger, T. H., Finzi, E., & Schulze, J. (2022). Treatment of depression with botulinum toxin. Toxins, 14(6), Article 383. https://doi.org/10.3390/toxins14060383
Antonucci, F., Rossi, C., Gianfranceschi, L., Rossetto, O., & Caleo, M. (2008). Long-distance retrograde effects of botulinum neurotoxin A. Journal of Neuroscience, 28(14), 3689–3696. https://doi.org/10.1523/JNEUROSCI.0375-08.2008
Matak, I., & Lacković, Z. (2014). Botulinum toxin A, brain and pain. Progress in Neurobiology, 119–120, 39–59. https://doi.org/10.1016/j.pneurobio.2014.06.001
Restani, L., Giribaldi, F., Manich, M., Bercsenyi, K., Menendez, G., Rossetto, O., Caleo, M., & Schiavo, G. (2012). Botulinum neurotoxins A and E undergo retrograde axonal transport in primary motor neurons. PLoS Pathogens, 8(12), Article e1003087. https://doi.org/10.1371/journal.ppat.1003087
Luvisetto, S., Marinelli, S., Cobianchi, S., & Pavone, F. (2021). Botulinum neurotoxins in central nervous system: An overview from animal models to human therapy. Toxins, 13(11), Article 751. https://doi.org/10.3390/toxins13110751
Ni, L., Chen, H., Xu, X., Sun, D., Cai, H., Wang, L., et al. (2023). Neurocircuitry underlying the antidepressant effect of retrograde facial botulinum toxin in mice. Cell & Bioscience, 13(1), Article 30. https://doi.org/10.1186/s13578-023-00964-1
Li, Y., Liu, J., Liu, X., Su, C. J., Zhang, Q. L., Wang, Z. H., Cao, L. F., Guo, X. Y., Huang, Y., Luo, W., & Liu, T. (2019). Antidepressant-like action of single facial injection of botulinum neurotoxin A is associated with augmented 5-HT levels and BDNF/ERK/CREB pathways in mouse brain. Neuroscience Bulletin, 35(4), 661–672. https://doi.org/10.1007/s12264-019-00367-8
Li, Y., Liu, G., & Luo, Q. (2021). Botulinum neurotoxin therapy for depression: Therapeutic mechanisms and future perspective. Frontiers in Psychiatry, 12, Article 584416. https://doi.org/10.3389/fpsyt.2021.584416
Ibragić, S., Matak, I., Dračić, A., Smajlović, A., Muminović, M., Proft, F., Sofić, E., Lacković, Z., & Riederer, P. (2016). Effects of botulinum toxin type A facial injection on monoamines and their metabolites in sensory, limbic and motor brain regions in rats. Neuroscience Letters, 617, 213–217. https://doi.org/10.1016/j.neulet.2016.02.020
Dayan, S. H., Lieberman, E. D., Thakkar, N. N., Larimer, K. A., & Anstead, A. (2008). Botulinum toxin A can positively impact first impression. Dermatologic Surgery, 34(Suppl. 1), S40–S47. https://doi.org/10.1111/j.1524-4725.2008.34241.x
Wollmer, M. A., de Boer, C., Kalak, N., Beck, J., Gotz, T., Schmidt, T., et al. (2012). Facing depression with botulinum toxin: A randomized controlled trial. Journal of Psychiatric Research, 46(5), 574–581. https://doi.org/10.1016/j.jpsychires.2012.01.027
Finzi, E., & Rosenthal, N. E. (2014). Treatment of depression with onabotulinumtoxinA: A randomized, double-blind, placebo-controlled trial. Journal of Psychiatric Research, 52, 1–6. https://doi.org/10.1016/j.jpsychires.2013.11.006
Magid, M., Reichenberg, J. S., Poth, P. E., Robertson, H. T., LaViolette, A. K., Kruger, T. H. C., & Wollmer, M. A. (2014). Treatment of major depressive disorder using botulinum toxin A: A 24-week randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry, 75(8), 837–844. https://doi.org/10.4088/JCP.13m08845
Brin, M. F., Durgam, S., Lum, A., James, L., Liu, J., Thase, M. E., et al. (2020). OnabotulinumtoxinA for the treatment of major depressive disorder: A phase 2 randomized, double-blind, placebo-controlled trial in adult females. International Clinical Psychopharmacology, 35(1), 19–28. https://doi.org/10.1097/YIC.0000000000000290
Ceolato-Martin, C., Chevallier-Collins, C., Clément, J. P., & Ranoux, D. (2024). OnabotulinumtoxinA in resistant depression: A randomized trial comparing two facial injection sites (OnaDEP Study). Depression and Anxiety, 2024, Article 1177925. https://doi.org/10.1155/2024/1177925
Qian, Y., Zhao, X., Zhong, L., Deng, Y., & Zhang, Z. (2020). Efficacy and safety of botulinum toxin vs. placebo in depression: A systematic review and meta-analysis of randomized controlled trials. Frontiers in Psychiatry, 11, Article 603087. https://doi.org/10.3389/fpsyt.2020.603087
Schulze, J., Sinke, C., Neumann, I., Wollmer, M. A., & Kruger, T. H. C. (2024). Effects of glabellar botulinum toxin injections on resting-state functional connectivity in borderline personality disorder. European Archives of Psychiatry and Clinical Neuroscience, 274, 97–107. https://doi.org/10.1007/s00406-023-01563-4
Demchenko, I., Tassone, V. K., Kennedy, S. H., Dunlop, K., & Bhat, V. (2024). Botulinum toxin injections for psychiatric disorders: A systematic review of the clinical trial landscape. Toxins, 16(4), Article 191. https://doi.org/10.3390/toxins16040191
Finzi, E., Rosenthal, N. E., & Heiser, M. A. (2024). Depression treatment: Is there a role for botulinum toxin type A? Microorganisms, 12(12), Article 2615. https://doi.org/10.3390/microorganisms12122615
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Dominika Dutkiewicz, Jacek Kowalski , Alia Echtay Yarbou, Rami Mallah, Dominika Julia Kozdroń, Michalina Weronika Nieścioruk, Paulina Szczepańska, Michał Tokarczyk, Andrzej Samujlik
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
